A randomized double blind comparison between single doses of Symbicort Turbuhaler (budesonide/formoterol combination), formoterol, salbutamol and placebo in repeated AMP-challenges in patients with mild-to-moderate asthma. Investigating the supplementary value of the budesonide component within Symbicort when tested in a model of slow onset acute asthma.

Trial Profile

A randomized double blind comparison between single doses of Symbicort Turbuhaler (budesonide/formoterol combination), formoterol, salbutamol and placebo in repeated AMP-challenges in patients with mild-to-moderate asthma. Investigating the supplementary value of the budesonide component within Symbicort when tested in a model of slow onset acute asthma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2011

At a glance

  • Drugs Budesonide/formoterol; Formoterol; Salbutamol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Feb 2010 Actual end date (Nov 2005) added as reported by ClinicalTrials.gov.
    • 15 Aug 2006 Status change
    • 29 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top